Ginkgo Bioworks Holdings Inc (DNA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

communications and ownership. It's my third year here at Ginkgo. I've spent much of that time working behind the scenes with our investor relations team on these earnings calls, but I'm thrilled to be joining you for the first time live on air. I'm joined by Jason Kelly, our co-founder and CEO, and Mark Dimitrick, our CFO. Thanks as always for joining us. We're looking forward to updating you on our progress. As a reminder, during the presentation today, we'll be making forward-looking statements which involve risks and uncertainties. Please refer to our filings with the SEC to learn more about these risks and uncertainties, including our most recent 10-K. Today, in addition to updating you on the quarter results, we're going to provide updates on our path towards adjusted EBITDA breakeven, traction with our government clients, as well as new offerings and opportunities emerging for our tools businesses. As usual, we'll end with a Q&A session, and I'll take questions from analysts, investors, and the public. You can submit those questions to us in advance via X, hashtag GinkgoResults, or email investors at ginkgobioworks.com. All right, over to you, Jason. Thanks, Daniel. We always start off with our mission here at Ginkgo, which is to make biology easier to engineer. And then we had three objectives. And I first showed these are close variants of these about a year ago when we were announced that we were going to be doing a major restructuring of the company. And these three objectives were to reach adjusted EBITDA break even by the end of 2026. And importantly, doing that while maintaining a cash margin of safety. In other words, we didn't want to get in a position where we were going to need to fundraise when we didn't want to, right? We wanted to be doing that if...